Till now corona virus has affected more that 200 countries and has infected more than 16 million people. Due to the complications developed by this virus around 644k people have lost their lives. It not only causes fever and cold but also develops critical infections in the body which affects the lungs and makes breathing a difficult choice. So far many scientists are working on this virus and are trying hard to understand them. But in order to save the lives of people, many countries were forced to impose lockdown since there is no other option left to reduce the fatality rate.
Also many researchers have developed few medicines such as remdesiver to cure mild and moderate corona symptoms but they are still unable to treat the critical patients and sometimes such medicines also don’t work for mild symptoms as well. So basically there is no proper and fixed treatment for this virus. The only thing which can be game changer is a vaccine which yet to be developed.
Many countries including India is already in the race of producing a valid vaccine which can generate antibodies against the virus. India’s first indigenous covid-19 vaccine known as COVAXIN was developed by bharat biotech in collaboration with ICMR ( Indian council of medical research ) and NIV ( national institute of virology ). The vaccine initially got a nod from DCGI ( Drug controller general of India ) to perform phase I and II human clinical trails. Also the phase I trail started in the early month of july and successfully completed the first part of phase -I trail.
The first part of phase – I trail of COVAXIN was completed on saturday at the PG institute of medical sciences, Rohtak. And fortunately all the results were found to be encouraging which gave COVAXIN a positive nod to go froward for it’s 2nd part of phase – I trail.
Track2Training 